Business
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:
About this update from Inmune Bio Inc.
[{"type":"text","content":"Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Monday, August 7, 2023 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Second Quarter Conference Call when reaching an operator. Date: August 7, 2023 Time: 4:30 PM Eastern Time Participant Dial-in: 1-877-407-0784Participant Dial-in (international): 1-201-689-8560Conference ID: 13739436 A live audio webcast of the call can be accessed clicking here or using this link:https://callme.viavid.com/viavid/?callme=true&passcode=13739436&h=true&info=company&r=true&B=6 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through August 14 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 13739436. About INmune Bio, Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease, and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward Looking Statements Clinical tria...